Pharmacometrics at FDA: Evolution and Impact on Decisions
暂无分享,去创建一个
[1] C. T. Viswanathan,et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.
[2] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[3] Yaning Wang,et al. Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications , 2005, The AAPS Journal.
[4] L B Sheiner,et al. Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.
[5] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[6] John J. Smith,et al. Defining "least burdensome means" under the Food and Drug Administration Modernization Act of 1997. , 2000, Food and drug law journal.
[7] Robert M Califf,et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. , 2006, JAMA.
[8] D. Rubin,et al. Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval , 2003, Clinical pharmacology and therapeutics.
[9] C Garnett,et al. Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.
[10] P. Marroum,et al. Utilisation of Pharmacokinetic-Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making , 2001, Clinical pharmacokinetics.